Loading...
XSTO
NANEXA
Market cap36mUSD
Jul 11, Last price  
2.23SEK
1D
-3.04%
1Q
71.54%
Jan 2017
-71.33%
IPO
-75.31%
Name

Nanexa AB

Chart & Performance

D1W1MN
P/E
P/S
14.36
EPS
Div Yield, %
Shrs. gr., 5y
53.35%
Rev. gr., 5y
70.11%
Revenues
24m
-16.93%
1,481,000658,695280,000105,000318,8401,710,0002,367,0002,374,0002,860,00029,327,00024,361,000
Net income
-25m
L-67.40%
-928,356-4,126,061-6,348,708-7,970,570-11,168,634-12,950,000-21,736,000-35,999,000-58,571,000-76,398,000-24,905,000
CFO
-26m
L-38.04%
563,994-3,293,259-6,405,349-5,072,358-6,756,523-9,417,000-16,827,000-25,128,000-7,871,000-42,658,000-26,430,000
Earnings
Aug 25, 2025

Profile

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
IPO date
Jun 17, 2015
Employees
21
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
24,361
-16.93%
29,327
925.42%
2,860
20.47%
Cost of revenue
(5,804)
(20,758)
23,227
Unusual Expense (Income)
NOPBT
30,165
50,085
(20,367)
NOPBT Margin
123.82%
170.78%
Operating Taxes
(108)
(112)
(64)
Tax Rate
NOPAT
30,273
50,197
(20,303)
Net income
(24,905)
-67.40%
(76,398)
30.44%
(58,571)
62.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
75,387
17,515
BB yield
-87.37%
-12.47%
Debt
Debt current
1,945
2,204
Long-term debt
2,197
2,087
4,068
Deferred revenue
Other long-term liabilities
1,000
3,766
18,220
Net debt
(8,095)
(61,137)
(74,912)
Cash flow
Cash from operating activities
(26,430)
(42,658)
(7,871)
CAPEX
(1,336)
(1,979)
(35,422)
Cash from investing activities
(28,120)
(34,248)
(35,422)
Cash from financing activities
(327)
60,892
18,814
FCF
31,968
51,045
(25,680)
Balance
Cash
10,292
65,168
81,182
Long term investments
1,000
2
Excess cash
9,074
63,703
81,041
Stockholders' equity
(298,354)
(222,131)
(155,440)
Invested Capital
371,477
325,759
288,520
ROIC
8.68%
16.34%
ROCE
41.25%
48.33%
EV
Common stock shares outstanding
135,696
70,148
50,696
Price
2.16
75.61%
1.23
-55.60%
2.77
-30.75%
Market cap
293,103
239.70%
86,282
-38.56%
140,427
-1.48%
EV
285,008
25,145
65,515
EBITDA
30,165
55,317
(9,863)
EV/EBITDA
9.45
0.45
Interest
461
487
666
Interest/NOPBT
1.53%
0.97%